- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02414243
Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy (RAF)
A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Rome, Italie
- Ospedale Pediatrico Bambino Gesù
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Children with documented cow's milk allergy, confirmed by one of the following criteria, within six months prior to study start (visit 2):
- Positive double-blind, placebo-controlled oral food challenge (DBPCFC) with cow's milk OR
- Positive open or single-blind oral food challenge with cow's milk carried out under the supervision of a specialist in children with clear immediate reactions and a positive test for specific IgE (in serum [sIgE>0,35 KUI/L] or skin prick test [SPT ≥ 3 mm]) OR
- Reported convincing allergic symptoms following an exposure to milk or a milk-containing food product and detectable serum milk-specific IgE or positive skin prick test
- Aged ≤12 years of age at screening.
- Expected consumption of a minimum of 250ml of study formula per day during the open challenge.
- Written informed consent from one or both parents (depending on the local legislation) or legal representative.
Exclusion Criteria:
- Children who receive breastfeeding at study enrolment.
- Had any chronic medical diseases, chromosomal or major congenital anomalies, or major gastrointestinal disease/abnormalities (other the CMPA); had immunodeficiency; antihistamine [excluding eye drops] use in 7 days prior to a food challenge or oral steroid use within 14 days prior to enrolment; unstable asthma; severe uncontrolled eczema;
- Severe anaphylactic reaction [required ≥ 2 doses of epinephrine] to milk or breast milk within the past 2 years;
- Existing illness that could interfere with formula acceptance or identification of allergic reactions.
- Investigator's uncertainty about the willingness or ability of the parents to comply with the protocol requirements.
- Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: New Amino Acid formula
New Amino-Acid based Infant Formula
|
Ordesa's Amino-Acid based Infant Formula
|
Comparateur actif: Control formula
Commercially available Amino Acid Formula
|
Commercially available Amino Acid Formula
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Hypoallergenicity as Assessed by Reaction to Amino-acid Based Infant Formula
Délai: 14 days
|
To demonstrate that the test formula does not cause immediate and/or delayed allergic reactions to a double blind placebo control food challenge (DBPCFC) and/or a subsequent open food challenge (OFC).
Incidence of immediate and/or delayed allergic reactions to the DBPCFC with the study product and/or active comparator and/or during the subsequent OPEN challenge phase of the study.
|
14 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Cow's Milk Allergy Related Symptoms
Délai: 14 days
|
Cow's Milk Allergy related Symptoms recorded at visit 1 and visit 4 using the Vandenplas symptom-based score (SBS). The scoring ranges from 0 to 33. Each symptom has a maximal score of 6, except respiratory symptoms where the maximal score is 3. If final score ≥ 12, the symptoms are likely cow's milk related. This could potentially be CMPA. If final score <12, the symptoms are less likely related to cow's milk. Look for other causes. |
14 days
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Claudia Banzato, MD, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- Chercheur principal: Maria Pedrosa, MD, Hospital Universitario La Paz
- Chercheur principal: Elena Alonso, MD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Chercheur principal: Montserrat Bosque, MD, Hospital Universitario Parc Taulí Sabadell, Barcelona, Spain
- Chercheur principal: Anna Mª Plaza, MD, Hospital Sant Joan de Déu, Barcelona, Spain
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RAF-01-015
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur New Amino Acid formula
-
Heilongjiang Feihe Dairy Co. Ltd.ComplétéComportement de santéChine
-
SMG-SNU Boramae Medical CenterInconnueDysfonction cognitive postopératoire
-
National Cancer Institute (NCI)Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest... et autres collaborateursComplétéCarcinome du sein HER2 positif | Cancer du sein de stade IA AJCC v7 | Cancer du sein de stade IB AJCC v7 | Cancer du sein de stade IIA AJCC v6 et v7 | Cancer du sein de stade IIB AJCC v6 et v7 | Cancer du sein de stade IIIA AJCC v7 | Adénocarcinome du seinÉtats-Unis, Canada, Pérou, Afrique du Sud